



ASX: MEM

Felix

A unique device to treat male infertility

Alison Coutts

Executive Chairman, *Memphasys Limited*



Disclaimer

For personal use only

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them.

This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, Memphasys and its affiliates and their

respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this presentation.

Pressing need for improvements in IVF

Memphasys

IVF:

- **Expensive** - up to \$10,000 per try, average of 2.2 tries before successful pregnancy, success not always possible
- **Physically and emotionally draining**
- **Increases risk of miscarriage, conceiving genetically impaired child**

What if there were a technology that:

- **Increased the likelihood of pregnancy, and**
- **Increased likelihood of giving birth to a healthy baby?**

What would that be worth?



Need to improve male fertility

Memphasys

Male Infertility

- A factor in ~50% of infertile couples
- Affects ~1/3rd of men over 40
- Has been rapidly increasing for the past few decades
 - environmental and lifestyle factors
- No meaningful advances in male sperm preparation treatments since the advent of IVF



Sperm quality,
rather than quantity,
is the issue

Human IVF market is large and rapidly growing

For personal use only

Key Human IVF market statistics

IVF treatments market size 2012/2020	US\$9.3bn / US\$21.6bn
Estimated no. IVF cycles pa	~6 million
IVF consumables market	US\$450m
Consumables cost per cycle	~\$400
Cost to patient per cycle (developing/developed countries)	~US\$2,000 / ~US\$10,000

Accessible Market¹

IVF treatments including ICSI (Intra Cytoplasmic Sperm Injection)	>\$600 million
ADD IUI (Intra Uterine Insertion)	> \$600 million
TOTAL	~\$1.2 Billion


¹ Assuming \$100 per cycle

MEM's technology provides better chance of success

Memphasys

- Unique, patented IP, proven to work
- Developed with Prof John Aitken, world-renowned fertility expert
- Separates the 'best' quality, least DNA-damaged sperm¹ from IVF semen samples
- Sperm DNA damage - A major factor affecting ability to conceive and to give birth to a healthy child

¹Best quality are most negatively charged



Memphasys' 'Felix' device has major advantages over current IVF sperm processing methods¹

Current methods	'Felix' device
<ul style="list-style-type: none">▪ 30-40 minute, manual	<ul style="list-style-type: none">✓ 3 minute, automated
<ul style="list-style-type: none">▪ Damage DNA	<ul style="list-style-type: none">✓ Gentle, no centrifuging, no cell damage
<ul style="list-style-type: none">▪ Limited in types of sperm samples they can treat	<ul style="list-style-type: none">✓ Can treat wide range of sperm samples
<ul style="list-style-type: none">▪ DNA-damaged sperm can unknowingly be selected	<ul style="list-style-type: none">✓ Selects best quality, least DNA-damaged sperm

¹ *Differential Gradient Centrifugation ('DGC') / 'Swim Up'*

Achievements and upcoming milestones

For personal use only



2008: Human births with earlier prototype device achieved

Mid 2017: Prototype device with re-usable cartridges built



2018 (now): Development of clinical system with single-use cartridges commenced


2019: 10-15 international IVF Key Opinion Leader (KOL) in-vitro study; CE Mark approval (Europe) possible by the end of 2019 cal. year



We've come a long way!

Memphasys

For personal use only



Corporate Statistics

For personal use only

Corporate Statistics	
Shares on issue	363,922,478
Market capitalisation	\$18.2 million (@ 5 cents)

Top 10 Shareholders		
1	Mr Andrew Ernest Goodall	24.39%
2	Peters Investments Pty Ltd	18.32%
3	Ms Alison Coutts	16.21%

Top 3 hold ~ 59%
Top 10 hold ~ 72%


Investment highlights

Unique, patented sperm separation technology

- Developed with world-renowned reproduction specialist - Professor John Aitken

Felix device for Human IVF

- Proven to work; low technology risk
- Need for better sperm processing for IVF
- Large, fast-growing global IVF market
- Development of Felix device for IVF clinics on track
- Relatively small funding and time frame before device is commercially available



Thank you

Alison Coutts

Executive Chairman, *Memphasys Ltd*

30-32 Richmond Rd, Homebush NSW 2140 Australia

Phone: +612 8415 7300